Bolt Biotherapeutics (NASDAQ:BOLT) Price Target Cut to $1.00 by Analysts at Stifel Nicolaus

Bolt Biotherapeutics (NASDAQ:BOLT) had its price target lowered by Stifel Nicolaus from $1.25 to $1.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a hold rating on the stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a report on Tuesday, March 25th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $1.00.

Bolt Biotherapeutics Stock Performance

NASDAQ:BOLT opened at $0.35 on Tuesday. Bolt Biotherapeutics has a 1 year low of $0.30 and a 1 year high of $1.32. The firm’s fifty day simple moving average is $0.38 and its 200 day simple moving average is $0.49. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $13.23 million, a PE ratio of -0.20 and a beta of 0.96.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.05. The company had revenue of $1.22 million for the quarter, compared to analyst estimates of $0.77 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. On average, sell-side analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently modified their holdings of BOLT. Citadel Advisors LLC bought a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $42,000. Velan Capital Investment Management LP bought a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $27,000. Squarepoint Ops LLC bought a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $26,000. Finally, Millennium Management LLC bought a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $25,000. 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.